At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
Fiasp® +2 moredrug
Likely dose
670G hybrid closed loop continuous subcutaneous insulin infusion systemfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory, Single-center, Randomized, Open Label, Active-control, Cross-over Trial Comparing the Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart (Fiasp®) Compared to NovoLog® Used in the Medtronic 670G Closed Loop System in Adults With Type 1 Diabetes
In Brief
A Phase 3 clinical trial evaluating Fiasp®, Novolog®, and 1 other intervention for Type 1 Diabetes Mellitus. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with T1DM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJun 2019
Primary CompletionMar 2020
Study CompletionApr 2020
TodayJul 2026
First PostedJun 6, 2019
Enrollment StartJun 11, 2019
Primary CompletionMar 9, 2020
Study CompletionApr 20, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.1 years ago
Interventions
Fiasp®drug
Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
Novolog®drug
Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
670G hybrid closed loop continuous subcutaneous insulin infusion systemdevice
CSII